Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform

Pictor Holdings Inc., a targeted proteomic platform company based in Carlsbad, California, has successfully closed a $7.5 million bridge round of growth capital, supported by existing investors. This funding, announced on June 30, 2026, brings the total capital raised by the company to approximately $30 million. The new capital will be directed towards expanding commercial partnerships, scaling platform development and manufacturing capabilities, and advancing translational studies in key human and animal health markets.

Pictor's innovative platform includes products such as PictArray®, PictImager®, and Pictorial© software, which allow laboratories to analyze up to 20 protein targets from a single sample in under two hours. This capability is designed to streamline workflows and reduce costs, making proteomic assays more accessible to a wider range of users, including those in pharmaceutical, reference laboratory, and animal health sectors. The company has already launched seven commercial products and established four strategic partnerships, marking a significant milestone in its commercial momentum since relocating its headquarters to the U.S.

The funds from this latest round will support Pictor's ongoing efforts to scale its operations and enhance its partner network. The company has plans to enter licensing agreements with multiple partners within the next 12 to 18 months, which could further solidify its market position. Additionally, Pictor is exploring a U.S.-based Series A financing round to fuel its next phase of growth, focusing on expanding commercial operations and platform development.

The targeted proteomics market is experiencing growth driven by increasing demand for advanced diagnostic tools and the need for cost-effective solutions in healthcare. Pictor's technology aligns with these trends by offering a more efficient alternative to traditional proteomic assays, which often require specialized settings and extensive resources. By enabling laboratories to generate more information from fewer samples, Pictor's platform not only supports One Health initiatives but also addresses sustainability goals within the industry.

As Pictor Holdings Inc. continues to build on its commercial success and expand its operational capabilities, the company is well-positioned to capitalize on the growing interest in proteomic technologies. The support from existing investors reflects confidence in Pictor's business model and its potential to drive advancements in both human and animal health. The broader implications of this funding round may signal a shift in the market as companies increasingly seek innovative solutions to meet the evolving demands of healthcare and research environments.